01:25 PM EST, 11/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We adjust our 12-month target price to USD48 from USD51, implying a 2025 P/E of 20.5x or 2026 P/E of 18.5x, broadly in line with its historical average. Qiagen's ( QGEN ) Q3 results announcement was particularly eventful, marked by a raised EPS guidance, the announcement of a proposed acquisition, and the news that the CEO will step down once a successor is appointed. EPS guidance was raised to USD2.38 using constant exchange rates (CER), while the 4%-5% CER sales growth outlook was reiterated. The announced acquisition of Parse Biosciences could help to strengthen Qiagen's ( QGEN ) position in sample technologies, though CEO Thierry Bernard's announced departure creates management uncertainty, in our view, on top of ongoing macroeconomic risks, particularly relating to tariffs. We continue to expect Diagnostic Solutions to be the main growth contributor, led by QuantiFERON (+12% CER in 9M) and QIAstat-Dx (+29% CER in 9M). We keep our 2025 EPS estimate of USD2.34 and our 2026 EPS estimate of USD2.60.